[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f22jkjhrz52kwj":5},{"data":4},[],{"data":6,"error":10},{"id":7,"documentId":8,"slug":9,"name":9,"proprietary_name":10,"non_proprietary_name":10,"is_proprietary":10,"active_ingredient":11,"administration_route":10,"available_strength":10,"dosage_form":10,"dose_schedule":10,"drug_unit":10,"is_available_generically":10,"mechanism_of_action":10,"overdosage":10,"warning":12,"species":13,"citations":14,"dose_schedules":23,"available_strengths":24,"label_statements":25,"drug_classes":26,"specialties":32,"medical_conditions":33,"animal_species":34},1884,"hlm4om58rvm0yingdcppdpcd","cefalexin",null,"Each ml contains:\r Active substance:\r Cefalexin (as cefalexin sodium): 180 mg\r Excipient(s):\r  Qualitative composition of excipients\r  and other constituents\r  Castor oil, hydrogenated\r  Triglycerides, medium-chain\r White to slightly yellow suspension for","Cross-resistance has been shown between cefalexin and other -lactams. Use of the\r\ncefalexin should be carefully considered when susceptibility testing has shown\r\nresistance to other -lactams because its effectiveness may be reduced.\r\nPseudomonas spp., Enterobacter spp. and other Proteus are resistant.",[],[15],{"covers":16,"source":19,"licence":20,"source_url":21,"retrieved_at":22},[17,18],"active_ingredient","warning","UK VMD Summary of Product Characteristics","Crown copyright, Open Government Licence v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002FProductInformationDatabase\u002Ffiles\u002FSPC_Documents\u002FSPC_3144048.PDF","2026-09-20",[],[],[],[27],{"id":28,"documentId":29,"slug":30,"name":31},988,"z5wselukrhdwvfxfnjhoxdhw","first-generation-cephalosporins","First-generation cephalosporins",[],[],[]]